New Delhi, Sep 16 (PTI) Two COVID-19 antibody treatments are no longer recommended by the World Health Organisation because Omicron and its subvariants have likely rendered them obsolete, according to a revised guideline published in the British Medical Journal.
In the same guideline update, WHO makes a conditional recommendation for the use of the antiviral drug remdesivir in patients with severe COVID-19, and a conditional recommendation against its use in patients with critical disease.
The WHO Guideline Development Group of international experts noted that antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19.
